Moon S Chen1, Primo N Lara, Julie H T Dang, Debora A Paterniti, Karen Kelly. 1. Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, California; Cancer Control, University of California, Davis Comprehensive Cancer Center, Sacramento, California.
Abstract
BACKGROUND: The National Institutes of Health (NIH) Revitalization Act of 1993 mandated the appropriate inclusion of minorities in all NIH-funded research. Twenty years after this act, the proportion of minority patients enrolled in cancer clinical trials remains persistently low. Clinical trials are vehicles for the development and evaluation of therapeutic and preventive agents under scientifically rigorous conditions. Without representation in trials, it is projected that disparities in the cancer burden for minorities will increase. METHODS: For this review article, the authors counted the frequency with which minorities were the primary focus of National Cancer Institute-sponsored clinical trials, examined citations from the PubMed database focusing on the search terms "NIH Revitalization Act of 1993" and "enhancing minority accrual to cancer clinical trials," and supplemented the review with their expertise in NIH-funded research related to minority accrual in cancer clinical trials. RESULTS: The reporting and analyses of data based on minorities in clinical trials remain inadequate. Less than 2% of the National Cancer Institute's clinical trials focus on any racial/minority population as their primary emphasis. The current review of the literature indicated that the percentage of authors who reported their study sample by race/ethnicity ranged from 1.5% to 58%, and only 20% of the randomized controlled studies published in a high-impact oncology journal reported analyzing results by race/ethnicity. Proportionately greater population increases in minorities, accompanied by their persistent and disproportionate cancer burden, reinforce the need for their greater representation in clinical trials. CONCLUSIONS: Renewing the emphasis for minority participation in clinical trials is warranted. Policy changes are recommended.
BACKGROUND: The National Institutes of Health (NIH) Revitalization Act of 1993 mandated the appropriate inclusion of minorities in all NIH-funded research. Twenty years after this act, the proportion of minority patients enrolled in cancer clinical trials remains persistently low. Clinical trials are vehicles for the development and evaluation of therapeutic and preventive agents under scientifically rigorous conditions. Without representation in trials, it is projected that disparities in the cancer burden for minorities will increase. METHODS: For this review article, the authors counted the frequency with which minorities were the primary focus of National Cancer Institute-sponsored clinical trials, examined citations from the PubMed database focusing on the search terms "NIH Revitalization Act of 1993" and "enhancing minority accrual to cancer clinical trials," and supplemented the review with their expertise in NIH-funded research related to minority accrual in cancer clinical trials. RESULTS: The reporting and analyses of data based on minorities in clinical trials remain inadequate. Less than 2% of the National Cancer Institute's clinical trials focus on any racial/minority population as their primary emphasis. The current review of the literature indicated that the percentage of authors who reported their study sample by race/ethnicity ranged from 1.5% to 58%, and only 20% of the randomized controlled studies published in a high-impact oncology journal reported analyzing results by race/ethnicity. Proportionately greater population increases in minorities, accompanied by their persistent and disproportionate cancer burden, reinforce the need for their greater representation in clinical trials. CONCLUSIONS: Renewing the emphasis for minority participation in clinical trials is warranted. Policy changes are recommended.
Authors: Meredith M Regan; Brian Leyland-Jones; Mark Bouzyk; Olivia Pagani; Weining Tang; Roswitha Kammler; Patrizia Dell'orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Patrick Neven; Marc Debled; Rudolf Maibach; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch; James M Rae; Giuseppe Viale Journal: J Natl Cancer Inst Date: 2012-03-06 Impact factor: 13.506
Authors: Kathleen M Diehl; Erin M Green; Armin Weinberg; Wayne A Frederick; Dennis R Holmes; Bettye Green; Arden Morris; Henry M Kuerer; Robert A Beltran; Jane Mendez; Venus Gines; David M Ota; Heidi Nelson; Lisa A Newman Journal: Ann Surg Oncol Date: 2011-06-17 Impact factor: 5.344
Authors: Elise D Cook; Kathryn B Arnold; John A Hermos; Worta McCaskill-Stevens; Sarah Moody-Thomas; Jeffrey L Probstfield; Sandra J Hamilton; Russell D Campbell; Karen B Anderson; Lori M Minasian Journal: Clin Trials Date: 2010-02 Impact factor: 2.486
Authors: James M Rae; Suzy Drury; Daniel F Hayes; Vered Stearns; Jacklyn N Thibert; Ben P Haynes; Janine Salter; Ivana Sestak; Jack Cuzick; Mitch Dowsett Journal: J Natl Cancer Inst Date: 2012-03-06 Impact factor: 13.506
Authors: Sam S Oh; Marquitta J White; Christopher R Gignoux; Esteban G Burchard Journal: Am J Respir Crit Care Med Date: 2016-02-15 Impact factor: 21.405
Authors: Anita Kurt; Lauren Semler; Jeanne L Jacoby; Melanie B Johnson; Beth A Careyva; Brian Stello; Timothy Friel; Mark C Knouse; Hope Kincaid; John C Smulian Journal: J Racial Ethn Health Disparities Date: 2016-09-08
Authors: Monica Webb Hooper; Taghrid Asfar; Marina Unrod; Asha Dorsey; John B Correa; Karen O Brandon; Vani N Simmons; Michael A Antoni; Tulay Koru-Sengul; David J Lee; Thomas H Brandon Journal: Ethn Dis Date: 2019-01-17 Impact factor: 1.847
Authors: Laura B Oswald; Judy Guitelman; Diana Buitrago; Joanna Buscemi; Francisco Iacobelli; Alejandra Perez-Tamayo; Frank Penedo; Betina Yanez Journal: Prog Community Health Partnersh Date: 2019
Authors: Meijing Wu; Jason Miska; Ting Xiao; Peng Zhang; J Robert Kane; Irina V Balyasnikova; James P Chandler; Craig M Horbinski; Maciej S Lesniak Journal: J Neurooncol Date: 2019-01-31 Impact factor: 4.130
Authors: Mark L Wieland; Jennifer A Weis; Marcelo M K Hanza; Sonja J Meiers; Christi A Patten; Matthew M Clark; Jeff A Sloan; Paul J Novotny; Jane W Njeru; Adeline Abbenyi; James A Levine; Miriam Goodson; Maria Graciela D Porraz Capetillo; Ahmed Osman; Abdullah Hared; Julie A Nigon; Irene G Sia Journal: Contemp Clin Trials Date: 2015-12-04 Impact factor: 2.226